Hostname: page-component-745bb68f8f-f46jp Total loading time: 0 Render date: 2025-01-28T01:52:27.420Z Has data issue: false hasContentIssue false
  • English
  • Français

5-HIAA in Cerebrospinal Fluid and Deficit Schizophrenic Characteristics

Published online by Cambridge University Press:  03 January 2018

John G. Csernansky ,
Roy J. King ,
William O. Faustman ,
James A. Moses Jr ,
Margaret E. Poscher  and
Kym F. Faull
John G. Csernansky*
Affiliation:
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine; Palo Alto Veterans Administration Medical Center, Psychiatry Service
Roy J. King
Affiliation:
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine
William O. Faustman
Affiliation:
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine; Palo Alto Veterans Administration Medical Center, Psychiatry Service
James A. Moses Jr
Affiliation:
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine; Palo Alto Veterans Administration Medical Center, Psychiatry Service
Margaret E. Poscher
Affiliation:
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine
Kym F. Faull
Affiliation:
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine
*
∗Palo Alto Veterans Administration Medical Center, 3801 Miranda Ave, Ward 4C2, Palo Alto, CA 94304, USA
Get access Rights & Permissions [Opens in a new window]

Abstract

Higher CSF 5-HIAA concentrations and lower CSF HVA concentrations have been associated with various measures of slowed motor behaviour and communication in schizophrenic patients. To derive a single, reliable measure of deficit characteristics in schizophrenic patients, we entered four items of the BPRS reflecting negative symptoms, a work history measure derived from the Strauss-Carpenter scale, and three subscale scores of the WAIS-R into a principal-components analysis to derive a single factor score. The CSF 5-HIAA concentrations were within the normal range of values, and correlated directly with this factor score, but CSF HVA concentrations were not associated with the deficit factor score. These findings add support to the hypothesis that brain serotonin function is associated with deficit schizophrenic characteristics.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 156 , Issue 4 , April 1990 , pp. 501 - 507
Copyright
Copyright © Royal College of Psychiatrists, 1990 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Andreasen, N. C. & Olsen, S. (1982) Negative versus positive schizophrenia. Archives of General Psychiatry 39, 789–794.CrossRefGoogle Scholar
Andreasen, N. C., Nasrallah, H. A., Dunn, V., et al (1986) Structural abnormalities in the frontal system in schizophrenia. Archives of General Psychiatry, 43, 136–144.CrossRefGoogle ScholarPubMed
Angrist, B., Rotrosen, J. & Gershon, S. (1980) Differential effects of amphetamine and neuroleptics on negative versus positive symptoms in schizophrenia. Psychopharmacology, 72, 17–19.CrossRefGoogle Scholar
Atkinson, L. & Cyr, J. J. (1984) Factor analysis of the WAIS–R: psychiatric and standardization samples. Journal of Consulting and Clinical Psychology, 52, 714–716.CrossRefGoogle ScholarPubMed
Berger, P. A., Faull, K. F., Kilkowski, J., et al (1980) CSF monoamine metabolites in depression and schizophrenia. American Journal of Psychiatry, 137, 174–180.Google ScholarPubMed
Bowers, M. B. (1974) Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry, 31, 50–54.CrossRefGoogle ScholarPubMed
Bowers, M. B. (1978) Serotonin systems in psychotic states. In Biochemistry of Mental Disorders (eds Usdin, E. & Mandell, A.). New York: Marcel Dekker, Inc.Google Scholar
Bowers, M. B., Heninger, G. R. & Gerbode, F. (1969) Cerebrospinal fluid 5HIAA and HVA in psychiatric patients. International Journal of Neuropharmacology, 8, 255–262.CrossRefGoogle Scholar
Carpenter, W. T. Jr, Heinrichs, D. W. & Alphas, L. D. (1985) Treatment of negative symptoms. Schizophrenia Bulletin, 11, 440–451.CrossRefGoogle ScholarPubMed
Carpenter, W. T. Jr, Heinrichs, D. W. & Wagman, A. M. I. (1988) Deficit and nondeficit forms of schizophrenia: the concept. American Journal of Psychiatry, 145, 578–583.Google ScholarPubMed
Ceulemans, D. L. S., Gelders, Y. G., Hoppenbrouwers, M. W. A., et al (1985) Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology, 85, 329–332.CrossRefGoogle ScholarPubMed
Crow, T. J. (1980) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 66–68.CrossRefGoogle ScholarPubMed
Endicott, J. & Spitzer, R. L. (1978) A diagnostic interview – the schedule for affective disorders and schizophrenia. Archives of General Psychiatry, 35, 837–844.CrossRefGoogle ScholarPubMed
Faull, K. F., King, R. J., Berger, P. A., et al (1984) Systems theory as a tool for integrating functional interactions among biogenic mines. In Catecholamines, Part C: Neuropharmacology and Central Nervous System - Therapeutic Aspects (eds Usdin, E., Carlsson, A., Dahlstrom, A., et al.) New York: Alan R. Liss Publisher.Google Scholar
Gateless, D., Stanley, M., Traskman-Bendz, L., et al (1984) The influence of the lying and sitting positions of the gradients of 5-HIAA and HVA in lumbar cerebrospinal fluid. Biological Psychiatry, 9, 1585–1589.Google Scholar
Gattaz, W. F., Waldmiier, P. & Beckman, H. (1982) CSF monoamine metabolites in schizophrenic patients. Acta Psychiatrica Scandinavica, 66, 350–360.CrossRefGoogle ScholarPubMed
Gerner, R. H., Fairbanks, L., Anderson, G. M., et al (1984) CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. American Journal of Psychiatry, 141, 1533–1540.Google ScholarPubMed
Guelfi, G. P., Faustman, W. O. & Csernansky, J. G. (1989) Independence of positive and negative symptoms in a population of schizophrenic patients. Journal of Nervous and Mental Disease, 177, 285–290.CrossRefGoogle Scholar
Heaton, R. K. & Crowley, T. J. (1981) Effects of psychiatric disorders and their somatic treatments on neuropsychological test results. In Handbook of Clinical Neuropsychology, (eds Filshov, S. B. & Boll, T. J.). New York: John Wiley & Sons.Google Scholar
King, R., Faull, K. F., Stahl, S. M., et al (1985) Serotonin and schizophrenia correlations between serotonergic activity and schizophrenic motor behavior. Psychiatry Research, 14, 235–240.CrossRefGoogle ScholarPubMed
Kirstein, L., Bowers, M. B. & Heninger, G. (1976) CSF amine metabolites, clinical symptoms and body movement in psychiatric patients. Biological Psychiatry, 11, 421–434.Google ScholarPubMed
Lezak, M. D. (1983) Neuropsychological Assessment. New York: Oxford University Press.Google Scholar
Lindstrom, L. A. (1985) Low HVA and normal 5HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Research, 41, 265–273.CrossRefGoogle Scholar
Matarazzo, J. D. (1972) Wechskr's Measurement and Appraisal of Adult Intelligence (5th edn). Baltimore: Williams & Wilkins Co.Google Scholar
Maxwell, A. E. (1977) Multivariate Analysis in Behavioural Research. London: Chapman & Hall.Google Scholar
Nasrallah, H. A., Kuperman, S., Hamra, B. J., et al (1983) Clinical differences between schizophrenic patients with and without large cerebral ventricles. Journal of Clinical Psychiatry, 44, 407–409.Google ScholarPubMed
Ninan, P. T., Van Kammen, D. P., Scheinin, M., et al (1984) CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. American Journal of Psychiatry, 141, 566–569.Google ScholarPubMed
Opler, L. A., Kay, S. R., Rosado, V., et al (1984) Positive and negative syndromes in chronic schizophrenic inpatients. Journal of Nervous and Mental Diseases, 172, 317–325.CrossRefGoogle ScholarPubMed
Overall, J. (1974) The Brief Psychiatric Rating Scale in psychopharmacology research. In Pharmacopsychiatry (ed. Pichot, P.). Basel: Karger.Google Scholar
Overall, J. & Gorham, D. R. (1963) The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.CrossRefGoogle Scholar
Parker, K. (1983) Factor analysis of the WAIS–R at nine age levels between 16 and 74 years. Journal of Consulting and Clinical Psychology, 51, 302–308.CrossRefGoogle Scholar
Pfefferbaum, A., Zipursky, R. B., Lim, K. O., et al (1988) CT evidence for generalized sulcal and ventricular enlargement in schizophrenia. Archives of General Psychiatry, 45, 633–640.CrossRefGoogle ScholarPubMed
Post, R. M., Fink, E., Carpenter, W. T., et al (1975) Cerebrospinal fluid amine metabolites in acute schizophrenia. Archives of General Psychiatry, 32, 1063–1069.CrossRefGoogle ScholarPubMed
Potkin, S. G., Weinberger, D. R., Linnoila, M., et al (1983) Low CSF 5-hydroxyindoleacetic acid in schizophrenic patients with enlarged cerebral ventricles. American Journal of Psychiatry, 140, 21–25.Google ScholarPubMed
Rubin, N. S., Harrow, M. & Pogue-Geile, M. (1987) The prognosis of deficit-negative and positive symptoms in post-hospital schizophrenia. Paper presented at the American Psychological Association, September, New York.Google Scholar
Sedvall, G. C. & Wode-Helgodt, B. (1980) Aberrant monoamine metabolite levels in CSF and family history of schizophrenia. Archives of General Psychiatry, 37, 1113–1116.CrossRefGoogle ScholarPubMed
Spitzer, R. L., Endicott, J. & Robins, E. (1978) Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry, 35, 773–791.CrossRefGoogle ScholarPubMed
Stahl, S. M., Uhr, S. B. & Berger, P. A. (1985) Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. Biological Psychiatry, 20, 1098–1102.CrossRefGoogle ScholarPubMed
Strauss, J. S. & Carpenter, W. T. (1974) The prediction of outcome in schizophrenia. II. Relationships between predictors and outcome variables: a report from the WHO International Pilot Study of Schizophrenia. Archives of General Psychiatry, 31, 37–42.CrossRefGoogle ScholarPubMed
Thiemann, S., Csernansky, J. G. & Berger, P. A. (1987) Rating scales in research: the case of negative symptoms. Psychiatry Research, 20, 47–55.CrossRefGoogle ScholarPubMed
Van Kammen, D. P., Mann, L. S., Scheinin, M., et al (1985) Decreased spinal fluid monoamine metabolites and norepinephrine in schizophrenic patients with brain atrophy. In Pathochemical Markers in Major Psychoses (eds Beckman, H. & Reiderer, P.). New York: Springer-Verlag.Google Scholar
Van Kammen, D. P., & Gelernter, J. (1987) Biochemical instability in schizophrenia II: the serotonin and gamma-aminobutyric acid systems. In Psychopharmacology: The Third Generation of Progress (ed. Meltzer, H. Y.). New York: Raven Press.Google Scholar
Van Praag, H. M. (1983) CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet, ii, 977–978.CrossRefGoogle Scholar
Wechsler, D. (1981) Wechsler Adult Intelligence Scale-Revised. New York: The Psychological Co.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.